| Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis AJ Van Der Meer, BJ Veldt, JJ Feld, H Wedemeyer, JF Dufour, F Lammert, ... Jama 308 (24), 2584-2593, 2012 | 1869 | 2012 |
| Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options IM Jacobson, SC Gordon, KV Kowdley, EM Yoshida, M Rodriguez-Torres, ... New England journal of medicine 368 (20), 1867-1877, 2013 | 1423 | 2013 |
| Mechanism of action of interferon and ribavirin in treatment of hepatitis C JJ Feld, JH Hoofnagle Nature 436 (7053), 967-972, 2005 | 1326 | 2005 |
| Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection JJ Feld, IM Jacobson, C Hézode, T Asselah, PJ Ruane, N Gruener, ... New England Journal of Medicine 373 (27), 2599-2607, 2015 | 1319 | 2015 |
| Treatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin JJ Feld, KV Kowdley, E Coakley, S Sigal, DR Nelson, D Crawford, ... New England Journal of Medicine 370 (17), 1594-1603, 2014 | 1133 | 2014 |
| Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus AASLD/IDSA HCV Guidance Panel, RT Chung, GL Davis, DM Jensen, ... Hepatology 62 (3), 932-954, 2015 | 831 | 2015 |
| Residual NADPH oxidase and survival in chronic granulomatous disease DB Kuhns, WG Alvord, T Heller, JJ Feld, KM Pike, BE Marciano, G Uzel, ... New England Journal of Medicine 363 (27), 2600-2610, 2010 | 590 | 2010 |
| Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection L Chen, I Borozan, J Feld, J Sun, LL Tannis, C Coltescu, J Heathcote, ... Gastroenterology 128 (5), 1437-1444, 2005 | 571 | 2005 |
| Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission GS Cooke, I Andrieux-Meyer, TL Applegate, R Atun, JR Burry, ... The lancet Gastroenterology & hepatology 4 (2), 135-184, 2019 | 507* | 2019 |
| Glecaprevir–pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection S Zeuzem, GR Foster, S Wang, A Asatryan, E Gane, JJ Feld, T Asselah, ... New England Journal of Medicine 378 (4), 354-369, 2018 | 476 | 2018 |
| Extrahepatic morbidity and mortality of chronic hepatitis C F Negro, D Forton, A Craxì, MS Sulkowski, JJ Feld, MP Manns Gastroenterology 149 (6), 1345-1360, 2015 | 467 | 2015 |
| Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome JJ Feld, H Dinh, T Arenovich, VA Marcus, IR Wanless, EJ Heathcote Hepatology 42 (1), 53-62, 2005 | 454 | 2005 |
| From non-A, non-B hepatitis to hepatitis C virus cure JM Pawlotsky, JJ Feld, S Zeuzem, JH Hoofnagle Journal of hepatology 62 (1), S87-S99, 2015 | 412 | 2015 |
| Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitis R Loomba, G Lutchman, DE Kleiner, M Ricks, JJ Feld, BB Borg, A Modi, ... Alimentary pharmacology & therapeutics 29 (2), 172-182, 2009 | 374 | 2009 |
| Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection AIHCVG Panel Clinical infectious diseases: an official publication of the Infectious …, 2018 | 363 | 2018 |
| Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores GN Ioannou, LA Beste, PK Green, AG Singal, EB Tapper, AK Waljee, ... Gastroenterology 157 (5), 1264-1278. e4, 2019 | 329 | 2019 |
| Increased caffeine consumption is associated with reduced hepatic fibrosis AA Modi, JJ Feld, Y Park, DE Kleiner, JE Everhart, TJ Liang, ... Hepatology 51 (1), 201-209, 2010 | 328 | 2010 |
| Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa–dependent manner G Ahlenstiel, RH Titerence, C Koh, B Edlich, JJ Feld, Y Rotman, ... Gastroenterology 138 (1), 325-335. e2, 2010 | 325 | 2010 |
| Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response JJ Feld, S Nanda, Y Huang, W Chen, M Cam, SN Pusek, LM Schweigler, ... Hepatology 46 (5), 1548-1563, 2007 | 322 | 2007 |
| Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis KR Reddy, M Bourlière, M Sulkowski, M Omata, S Zeuzem, JJ Feld, ... Hepatology 62 (1), 79-86, 2015 | 314 | 2015 |
